Diaphragm Ultrasound to Evaluate the Antagonistic Effect of Sugammadex

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The use of muscle relaxants is an indispensable in the general anesthesia but is prone to accidents, which are often related to residual muscle relaxant. Therefore, how to timely and effectively eliminate the residual effect of muscle relaxants after surgery has become an urgent clinical problem. Rocuronium is a non-depolarizing muscle relaxant that is primarily metabolized by the liver. Patients with liver dysfunction can affect the metabolic process of rocuronium, thereby delaying the recovery of muscle relaxation. Sugammadex (SUG) is a novel specific antagonist of aminosteroid muscle relaxants, which can effectively antagonize muscle relaxants at different depths. However, whether liver dysfunction affects the antagonistic effect of SUG against rocuronium has not been reported yet. Therefore, the investigators hypothesize that with the increase of patients' liver Child-Pugh grade, the recovery time of rocuronium antagonized by the same dose of SUG after surgery will be prolonged, and the incidence of muscle relaxation residual will be increased in the short term.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wuhan Union Hospital, China

Criteria

Inclusion Criteria:

• 1.Age between 18 and 65 years old.

• 2.Patients scheduled for laparoscopic radical resection of liver cancer under general anesthesia.

• 3.Patients ASA classification Ⅰ-Ⅲ.

• 4.Body mass index 18.5 kg/m2 ~ 24.9 kg/m2

• 5.Able to give informed consent.

• 6.The surgical position is suitable for BIS monitoring and muscle relaxation monitoring.

Exclusion Criteria:

• 1.Patients with allergic to rocuronium and SUG.

• 2.Patients with central and peripheral nervous system diseases, such as polio, Parkinson's disease, peripheral neuropathy, etc..

• 3.Patients with neuromuscular system diseases, such as multiple sclerosis, myasthenia gravis, atrophic myotonia, etc..

• 4.Patients with diaphragm dysfunction, pneumothorax, pleural effusion, mediastinal pneumatosis.

• 5.Pregnant women or nursing mothers.

• 6.Judging by the researchers, patients with other conditions who are unsuitable for clinical trials.